Denosumab-related osteonecrosis of the jaw may not be a subject of teriparatide treatment

wbldb

Park, Kyung-Su¹; Jung, Seung Min¹; Park, Yune-Jung¹; Kim, Ki-Jo¹

J Bone Miner Res. October 2022;37(10):2044-2045

Cited Works (3)

Year	Entry
2018	Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen J-EB, McClung M, Roux C, Törring O, Valter I, Wang AT, Brown JP. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. February 2018;33(2):190-198.
2015	Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie S-AM. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. September 19-25, 2015;386(9999):1147.
2022	Everts-Graber J, Lehmann D, Burkard J-P, Schaller B, Gahl B, Häuselmann H, Studer U, Ziswiler H-R, Reichenbach S, Lehmann T. Risk of osteonecrosis of the jaw under denosumab compared to bisphosphonates in patients with osteoporosis. J Bone Miner Res. February 2022;37(2):340-348.

Cited By (1)

Year	Entry
2022	Everts-Graber J, Burkhard J-P, Schaller B, Reichenbach S, Lehmann T. Reply to potential issues with the use of teriparatide after denosumab-related osteonecrosis of the jaw. J Bone Miner Res. October 2022;37(10):2046-2047.